Yen Yun 4

4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Jul 2, 2024

Form 4

Period: 2024-06-30

Director

Transactions

Award
Options to Purchase Common Stock
2024-06-30+10,000→ 10,000 total
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying)
Award
Options to Purchase Common Stock
2024-06-30+4,527→ 4,527 total
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (4,527 underlying)

Holdings

Options to Purchase Common Stock
Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying)
5,000
Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying)
10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying)
10,000
Warrants to Purchase Common Stock
(indirect: By Sino-American Cancer FDD)
Exercise: $57.00From: 2020-11-30Exp: 2025-11-30→ Common (5,263 underlying)
5,263
Options to Purchase Common Stock
Exercise: $16.80From: 2018-08-04Exp: 2023-08-04→ Common (3,333 underlying)
3,333
Options to Purchase Common Stock
Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying)
833

Footnotes (2)

[F1]Effective June 30, 2024, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2024).
[F2]Effective June 30, 2024, the reporting person was granted stock options to purchase an aggregate of 4,527 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the Reporting Person under the Board Compensation Plan.

Documents

1 file